ClinicalTrials.gg
CompletedNCT01945294Updated Jul 12, 2018Results posted

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

A Phase 3 interventional study of Boceprevir and Peg-interferon alfa-2b in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing boceprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. boceprevir · Hepatitis C, Chronic.

Enrollment
9th of 20
257 · median 239
Started
2013
with 4 others
Phase 3
12 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
14 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing boceprevir in Hepatitis C, Chronic, this one is the 9th largest by enrollment, is one of 5 that started in 2013, is one of 12 in phase 3, and was the 19th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 20 studies testing boceprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About boceprevir

boceprevir: first FDA approval 2011 (VICTRELIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing boceprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to estimate the difference in the efficacy between a 16-week treatment regimen of boceprevir (BOC) in combination with peg-intron alpha 2b (P) plus ribavirin (R) (BOC + PR) and a 28-week treatment regimen of BOC + PR in previously untreated participants with chronic hepatitis C (CHC) genotype 1 in Asia who achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA).

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • weigh ≥ 40 kg and ≤ 125 kg
  • have CHC genotype 1 infection
  • has had a liver or non-invasive liver fibrosis test that shows no evidence of cirrhosis and hepatocellular carcinoma
  • must agree that the participant and the participant's partner will each use acceptable methods of for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations (for a female participant who is of or male participant with female sexual partner who is of childbearing potential)

Exclusion criteria

Exclusion Criteria:

  • participates in any other interventional clinical trial within 30 days of the screening visit in this trial or intends to participate in another interventional clinical trial during participation in this trial
  • is co-infected with (HIV) or virus
  • has evidence or history of chronic hepatitis not caused by , including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and hepatitis
  • has evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
  • has evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • has evidence of active or suspected , or a history of malignancy, within the last 5 years
  • has been previously treated with an interferon or ribavirin regimen or HCV direct acting anti-viral regimen, or treated for hepatitis C with any medication
  • taking/plans to take significant inducers of inhibitors of Cytochrome P450 3A4 () substrates 2 weeks prior to start of study medications, or herbal supplements, including but not limited to St. John's Wort 2 weeks prior to start of study medications (Day 1)
  • has pre-existing psychiatric condition(s)
  • has a clinical diagnosis of substance abuse
  • has any known medical condition that could interfere with the participation in and completion of the trial including immunologically-mediated disease, chronic pulmonary disease, or current or history of any cardiac abnormalities/dysfunction
  • is pregnant or nursing (for female participant) or female partner intends to become pregnant (for male participant)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Arm 1: 16-week Treatment Arm

    All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).

    Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin

  • Experimental
    Arm 2: 28-week Treatment Arm

    All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).

    Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin

  • Experimental
    Arm 3: 48-week Treatment Arm

    All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).

    Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin

Interventions

  • 800 mg three times daily orally

    Also known as: MK-3034

  • 1.5 mcg/kg weekly subcutaneously

    Also known as: PegIntron

  • 800-1400 mg twice-daily divided orally based on body weight

    Also known as: Rebetol

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]

    SVR12 was declared when participants who had undetectable HCV RNA (HCV RNA \< Lower Limit of Quantification \[LLoQ\]) after the 12-week lead-in also had undetectable HCV RNA 12 weeks after completing their assigned BOC treatment regimen. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

    Time frame: Follow-up Week (FW) 12 (up to 40 weeks)

Secondary outcomes

  1. Percentage of Participants With Undetectable HCV RNA Across Treatment

    The percentage of participants with undetectable HCV RNA (HCV RNA \<LLoQ) at TW4, TW8, and TW12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

    Time frame: TW4, TW8, and TW12

  2. Percentage of Participants Achieving SVR12 Among Participants With Undetectable HCV RNA Across Treatment

    The percentage of participants achieving SVR12 who had undetectable HCV RNA (HCV RNA \<LLoQ) at Week 4, Week 8, and Week 12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

    Time frame: TW4, TW8, and TW12

  3. Percentage of Participants With Relapse

    The percentage of viral relapse (defined as confirmed HCV RNA \>15 IU/mL after End-of-Treatment \[EOT\]) among participants who had undetectable HCV RNA at EOT was determined for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

    Time frame: From EOT to FW12 (up to 12 weeks)

  4. Percentage of Participants With Neutropenia

    The percentage of participants with neutropenia (neutrophil count \<0.75 x10\^9/L) is summarized for each arm.

    Time frame: Up to 60 weeks

  5. Percentage of Participants With Anemia

    The percentage of participants with anemia (hemoglobin \[Hgb\] \<10 g/dL) was determined in each arm.

    Time frame: Up to 60 weeks

  6. Percentage of Participants With Dose Discontinuation Due to Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The percentage of participants who discontinued from BOC, BOC + RBV, or all medications due to an AE are reported.

    Time frame: From TW1 through TW48

  7. Percentage of Participants With Treatment-Related Serious AEs (SAEs)

    A SAE is any AE that results in death, is life threatening, results in persistent or significant disability, results in or prolongs an existing inpatient hospitalization, is a congenital birth defect, is a cancer, is associated with an overdose, or is another important medical event.

    Time frame: Up to 60 weeks

07

Results

Posted Nov 23, 2016

Participant flow

Treatment-naïve adult male and female participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection were recruited in the Asia-Pacific region.

Period 1: 12-Week PR + BOC Lead-In
Participant flow — Period 1: 12-Week PR + BOC Lead-In
MilestoneAll Treated ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Started257000
Completed236000
Not completed21000
Period 2: BOC+ PR Treatment & Follow-up
Participant flow — Period 2: BOC+ PR Treatment & Follow-up
MilestoneAll Treated ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Started010210529
Completed0979723
Not completed0586

Outcome measures

PrimaryPercentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]

SVR12 was declared when participants who had undetectable HCV RNA (HCV RNA \< Lower Limit of Quantification \[LLoQ\]) after the 12-week lead-in also had undetectable HCV RNA 12 weeks after completing their assigned BOC treatment regimen. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

Time frame:
Follow-up Week (FW) 12 (up to 40 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]70.681.9—
Statistical analysis
  • Arm 1: 16-week Treatment Arm vs Arm 2: 28-week Treatment Arm · Difference in svr12 percentage: -11.4 · 95% CI -23.2 to 0.4
SecondaryPercentage of Participants With Undetectable HCV RNA Across Treatment

The percentage of participants with undetectable HCV RNA (HCV RNA \<LLoQ) at TW4, TW8, and TW12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

Time frame:
TW4, TW8, and TW12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Undetectable HCV RNA Across Treatment
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
TW424.817.10.0
TW8100.0100.00.0
TW1299.0100.069.0
SecondaryPercentage of Participants Achieving SVR12 Among Participants With Undetectable HCV RNA Across Treatment

The percentage of participants achieving SVR12 who had undetectable HCV RNA (HCV RNA \<LLoQ) at Week 4, Week 8, and Week 12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

Time frame:
TW4, TW8, and TW12
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving SVR12 Among Participants With Undetectable HCV RNA Across Treatment
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
% Undetectable HCV RNA at TW4 (n=25, 18, 0)24.514.30.0
% Undetectable HCV RNA at TW8 (n=101, 104, 0)69.681.00.0
% Undetectable HCV RNA at TW12 (n=100, 103, 20)68.680.041.4
SecondaryPercentage of Participants With Relapse

The percentage of viral relapse (defined as confirmed HCV RNA \>15 IU/mL after End-of-Treatment \[EOT\]) among participants who had undetectable HCV RNA at EOT was determined for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.

Time frame:
From EOT to FW12 (up to 12 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Relapse
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Percentage of Participants With Relapse20.41.10.0
SecondaryPercentage of Participants With Neutropenia

The percentage of participants with neutropenia (neutrophil count \<0.75 x10\^9/L) is summarized for each arm.

Time frame:
Up to 60 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Neutropenia
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Percentage of Participants With Neutropenia10.812.44.0
SecondaryPercentage of Participants With Anemia

The percentage of participants with anemia (hemoglobin \[Hgb\] \<10 g/dL) was determined in each arm.

Time frame:
Up to 60 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anemia
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Percentage of Participants With Anemia33.343.826.0
SecondaryPercentage of Participants With Dose Discontinuation Due to Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The percentage of participants who discontinued from BOC, BOC + RBV, or all medications due to an AE are reported.

Time frame:
From TW1 through TW48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose Discontinuation Due to Adverse Events (AEs)
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Discontinued from BOC2.97.616.0
Discontinued from BOC + R0.05.78.0
Discontinued from all Study Medication0.05.78.0
SecondaryPercentage of Participants With Treatment-Related Serious AEs (SAEs)

A SAE is any AE that results in death, is life threatening, results in persistent or significant disability, results in or prolongs an existing inpatient hospitalization, is a congenital birth defect, is a cancer, is associated with an overdose, or is another important medical event.

Time frame:
Up to 60 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-Related Serious AEs (SAEs)
Percentage of ParticipantsArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
Percentage of Participants With Treatment-Related Serious AEs (SAEs)2.93.84.0

Adverse events

Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: 16-week Treatment Arm—9/102 (8.8%)96/102 (94.1%)
Arm 2: 28-week Treatment Arm—6/105 (5.7%)98/105 (93.3%)
Arm 3: 48-week Treatment Arm—4/50 (8%)46/50 (92%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
AnaemiaBlood and lymphatic system disorders1/1022/1051/50
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1020/1051/50
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1020/1051/50
DepressionPsychiatric disorders0/1020/1051/50
NeutropeniaBlood and lymphatic system disorders1/1020/1050/50
IleusGastrointestinal disorders1/1020/1050/50
VomitingGastrointestinal disorders1/1020/1050/50
PyrexiaGeneral disorders1/1020/1050/50
Biliary dilatationHepatobiliary disorders1/1020/1050/50
PneumoniaInfections and infestations1/1020/1050/50
Most frequent other events
Showing 10 of 37
Most frequent other events
EventArm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment Arm
AnaemiaBlood and lymphatic system disorders33/10244/10512/50
PyrexiaGeneral disorders23/10223/10517/50
AlopeciaSkin and subcutaneous tissue disorders23/10234/1058/50
Decreased appetiteMetabolism and nutrition disorders18/10224/10512/50
DizzinessNervous system disorders17/10225/1059/50
MyalgiaMusculoskeletal and connective tissue disorders23/10222/1057/50
NauseaGastrointestinal disorders16/10215/10511/50
DysgeusiaNervous system disorders15/10223/1058/50
HeadacheNervous system disorders17/10218/1058/50
RashSkin and subcutaneous tissue disorders8/10218/1054/50

Baseline characteristics

The total number of participants in Arm 3 (i.e., n=50) includes participants who completed the BOC + PR lead-in and were allocated at Week 12 based on having detectable HCV RNA (n=29), as well as participants who began the BOC + PR lead-in but discontinued prior to Week 12 (n=21).

Age, Continuous
Age, Continuous(Years)Arm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment ArmTotal
Mean44.1 ± 11.144.6 ± 10.646.5 ± 11.844.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: 16-week Treatment ArmArm 2: 28-week Treatment ArmArm 3: 48-week Treatment ArmTotal
Female434124108
Male596426149
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Aug 2015, 21 months.

Results were first posted in Nov 2016, 1 year 3 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2013
First posted
Sep 18, 2013
StartActual
Oct 10, 2013
Primary completionActual
Aug 5, 2015
CompletionActual
Nov 4, 2015
Results first posted
Nov 23, 2016
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01945294
Responsible party
Sponsor
First posted
Sep 18, 2013
Start date
Oct 10, 2013
Primary completion
Aug 5, 2015
Completion
Nov 4, 2015
Results posted
Nov 23, 2016
Last update
Jul 12, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Boceprevir · Peginterferon alfa-2b · Ribavirin

Start the discussion